Vaccination approach to anti-angiogenic treatment of cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1855, Issue 2, 2015, Pages 155-171

  Wentink, Madelon Q ^a   Huijbers, Elisabeth J M ^a   de Gruijl, Tanja D ^a   Verheul, Henk M W ^a   Olsson, Anna Karin ^b   Griffioen, Arjan W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; Immunology; Tumor vasculature; Vaccination

Indexed keywords

BACTERIAL RECOMBINANT ANTIGEN VACCINE; CANCER VACCINE; CIGB 247; DC VACCINE; DNA PEPTIDE VACCINE; DNA VACCINE; ELPAMOTIDE; FREUND ADJUVANT; FUSION DC VACCINE; FUSION DNA VACCINE; FUSION PROTEIN VACCINE; GLUTARALDEHYDE FIXED ENDOTHELIAL CELL VACCINE; HLA RESTRICTED PEPTIDE VACCINE; KINOID; MINIGENE DNA VACCINE; PARAFORMALDEHYDE FIXED XENOGENEIC ENDOTHELIAL CELL VACCINE; PEPTIDE VACCINE; PROTEIN VACCINE; T4 MVEGFR2 PHAGE VACCINE; UNCLASSIFIED DRUG; VIABLE XENOGENEIC ENDOTHELIAL CELL VACCINE; XENOGENEIC DNA VACCINE; XENOGENEIC PROTEIN VACCINE; ANGIOGENESIS INHIBITORS;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BLADDER CARCINOMA; BRAIN TUMOR; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER IMMUNIZATION; CANCER INHIBITION; CARCINOMA; CELLULAR IMMUNITY; COLON CANCER; COLON CARCINOMA; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; ERYTHEMA; FEVER; FIBROSARCOMA; HUMAN; HUMORAL IMMUNITY; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INJECTION SITE REACTION; KIDNEY CARCINOMA; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LUNG METASTASIS; LYMPHOMA; MELANOMA; MELANOMA B16; METASTASIS INHIBITION; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PROTEINURIA; REVIEW; SKIN MANIFESTATION; SOFT TISSUE SARCOMA; SOLID TUMOR; SPONTANEOUS CUTANEOUS SOFT TISSUE SARCOMA; HUMANS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; VACCINATION;

ANGIOGENESIS INHIBITORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VACCINATION;

EID: 84922373092     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.01.005     Document Type: Review

References (141)

1. Alfaro C., Suarez N., Gonzalez A., Solano S., Erro L., Dubrot J., Palazon A., Hervas-Stubbs S., Gurpide A., Lopez-Picazo J.M., Grande-Pulido E., Melero I., Perez-Gracia J.L. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br. J. Cancer 2009, 100:1111-1119.
2. Allegra C.J., Yothers G., O'Connell M.J., Sharif S., Petrelli N.J., Lopa S.H., Wolmark N. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol. 2013, 31:359-364.
3. Arigoni M., Barutello G., Lanzardo S., Longo D., Aime S., Curcio C., Iezzi M., Zheng Y., Barkefors I., Holmgren L., Cavallo F. A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. Angiogenesis 2012, 15:305-316.
4. St.Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202.
5. Becker J.C., Andersen M.H., Hofmeister-Muller V., Wobser M., Frey L., Sandig C., Walter S., Singh-Jasuja H., Kampgen E., Opitz A., Zapatka M., Brocker E.B., Thor S.P., Schrama D., Ugurel S. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol. Immunother. 2012, 61:2091-2103.
6. Bequet-Romero M., Morera Y., Ayala-Avila M., Ancizar J., Soria Y., Blanco A., Suarez-Alba J., Gavilondo J.V. CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors. Vaccine 2012, 30:1790-1799.
7. Burrows F.J., Derbyshire E.J., Tazzari P.L., Amlot P., Gazdar A.F., King S.W., Letarte M., Vitetta E.S., Thorpe P.E. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res. 1995, 1:1623-1634.
8. Butts C., Socinski M.A., Mitchell P.L., Thatcher N., Havel L., Krzakowski M., Nawrocki S., Ciuleanu T.E., Bosquee L., Trigo J.M., Spira A., Tremblay L., Nyman J., Ramlau R., Wickart-Johansson G., Ellis P., Gladkov O., Pereira J.R., Eberhardt W.E., Helwig C., Schroder A., Shepherd F.A. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014, 15:59-68.
9. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
10. Chen X.Y., Zhang W., Zhang W., Wu S., Bi F., Su Y.J., Tan X.Y., Liu J.N., Zhang J. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin. Cancer Res. 2006, 12:5834-5840.
11. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
12. De M.L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., Braga M., Di C., Doglioni V.C., Protti M.P. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 2011, 208:469-478.
13. Della P.M., Danova M., Rigolin G.M., Brugnatelli S., Rovati B., Tronconi C., Fraulini C., Russo R.A., Riccardi A., Castoldi G. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 2005, 68:276-284.
14. Dings R.P., Vang K.B., Castermans K., Popescu F., Zhang Y., Oude Egbrink M.G., Mescher M.F., Farrar M.A., Griffioen A.W., Mayo K.H. Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin. Cancer Res. 2011, 17:3134-3145.
15. Dirkx A.E., Oude Egbrink M.G., Castermans K., van der Schaft D.W., Thijssen V.L., Dings R.P., Kwee L., Mayo K.H., Wagstaff J., Bouma-ter Steege J.C., Griffioen A.W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006, 20:621-630.
16. Dirkx A.E., Oude Egbrink M.G., Kuijpers M.J., van der Niet S.T., Heijnen V.V., Bouma-ter Steege J.C., Wagstaff J., Griffioen A.W. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003, 63:2322-2329.
17. Dong Y., Qian J., Ibrahim R., Berzofsky J.A., Khleif S.N. Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J. Immunother. 2006, 29:32-40.
18. Dubensky T.W., Reed S.G. Adjuvants for cancer vaccines. Semin. Immunol. 2010, 22:155-161.
19. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 2011, 8:210-221.
20. Erdag G., Schaefer J.T., Smolkin M.E., Deacon D.H., Shea S.M., Dengel L.T., Patterson J.W., Slingluff C.L. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012, 72:1070-1080.
21. Escudier B., Bellmunt J., Negrier S., Bajetta E., Melichar B., Bracarda S., Ravaud A., Golding S., Jethwa S., Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 2010, 28:2144-2150.
22. Facciponte J.G., Ugel S., De S.F., Li C., Wang L., Nair G., Sehgal S., Raj A., Matthaiou E., Coukos G., Facciabene A. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J. Clin. Invest. 2014, 124:1497-1511.
23. Femel J., Huijbers E.J., Saupe F., Cedervall J., Zhang L., Roswall P., Larsson E., Olofsson H., Pietras K., Dimberg A., Hellman L., Olsson A.K. Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer. Oncotarget 2014, 23:12418-12427.
24. Ferguson H.J., Wragg J., Ismail T., Bicknell R. Vaccination against tumour blood vessels in colorectal cancer. Eur. J. Surg. Oncol. 2014, 40:133-136.
25. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
26. Fricke I., Mirza N., Dupont J., Lockhart C., Jackson A., Lee J.H., Sosman J.A., Gabrilovich D.I. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 2007, 13:4840-4848.
27. Fu C., Bardhan S., Cetateanu N.D., Wamil B.D., Wang Y., Yan H.P., Shi E., Carter C., Venkov C., Yakes F.M., Page D.L., Lloyd R.S., Mernaugh R.L., Hellerqvist C.G. Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. Clin. Cancer Res. 2001, 7:4182-4194.
28. Gabitass R.F., Annels N.E., Stocken D.D., Pandha H.A., Middleton G.W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 2011, 60:1419-1430.
29. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., Carbone D.P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92:4150-4166.
30. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096-1103.
31. Gabrilovich D.I., Ishida T., Nadaf S., Ohm J.E., Carbone D.P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 1999, 5:2963-2970.
32. Gavilondo J.V., Hernandez-Bernal F., Ayala-Avila M., de la Torre A.V., de la Torre J., Morera-Diaz Y., Bequet-Romero M., Sanchez J., Valenzuela C.M., Martin Y., Selman-Housein K.H., Garabito A., Lazo O.C. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine 2014, 32:2241-2250.
33. Giuliano S., Pages G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 2013, 95:1110-1119.
34. Griffioen A.W. Recognition of the Tumor Vasculature as a Target for Cancer Vaccination 2014.
35. Griffioen A.W. Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level?. Trends Cardiovasc. Med. 2007, 17:171-176.
36. Griffioen A.W., Damen C.A., Blijham G.H., Groenewegen G. Endoglin/CD 105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res. Treat. 1996, 39:239-242.
37. Griffioen A.W., Damen C.A., Blijham G.H., Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996, 88:667-673.
38. Griffioen A.W., Damen C.A., Martinotti S., Blijham G.H., Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 1996, 56:1111-1117.
39. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52:237-268.
40. Griffioen A., Weiss A., Berndsen R., Abdul U., Te Winkel M., Nowak-Sliwinska P. The Emerging Quest for the Optimal Angiostatic Combination Therapy 2014.
41. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
42. Haller B.K., Brave A., Wallgard E., Roswall P., Sunkari V.G., Mattson U., Hallengard D., Catrina S.B., Hellstrom M., Pietras K. Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma. Oncogene 2010, 29:4276-4286.
43. Hamano Y., Zeisberg M., Sugimoto H., Lively J.C., Maeshima Y., Yang C., Hynes R.O., Werb Z., Sudhakar A., Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003, 3:589-601.
44. Hayashi H., Kurata T., Fujisaka Y., Kawakami H., Tanaka K., Okabe T., Takeda M., Satoh T., Yoshida K., Tsunoda T., Arao T., Nishio K., Nakagawa K. Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. Cancer Sci. 2013, 104:98-104.
45. He Q.M., Wei Y.Q., Tian L., Zhao X., Su J.M., Yang L., Lu Y., Kan B., Lou Y.Y., Huang M.J., Xiao F., Liu J.Y., Hu B., Luo F., Jiang Y., Wen Y.J., Deng H.X., Li J., Niu T., Yang J.L. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J. Biol. Chem. 2003, 278:21831-21836.
46. Hodi F.S., Lawrence D., Lezcano C., Wu X., Zhou J., Sasada T., Zeng W., Giobbie-Hurder A., Atkins M.B., Ibrahim N., Friedlander P., Flaherty K.T., Murphy G.F., Rodig S., Velazquez E.F., Mihm M.C., Russell S., DiPiro P.J., Yap J.T., Ramaiya N., Van den Abbeele A.D., Gargano M., McDermott D. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2014, 2:632-642.
47. Holmgren L., Ambrosino E., Birot O., Tullus C., Veitonmaki N., Levchenko T., Carlson L.M., Musiani P., Iezzi M., Curcio C., Forni G., Cavallo F., Kiessling R. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9208-9213.
48. Honma I., Kitamura H., Torigoe T., Takahashi A., Tanaka T., Sato E., Hirohashi Y., Masumori N., Tsukamoto T., Sato N. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol. Immunother. 2009, 58:1801-1807.
49. Huang H., Bhat A., Woodnutt G., Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 2010, 10:575-585.
50. Huang Y., Yuan J., Righi E., Kamoun W.S., Ancukiewicz M., Nezivar J., Santosuosso M., Martin J.D., Martin M.R., Vianello F., Leblanc P., Munn L.L., Huang P., Duda D.G., Fukumura D., Jain R.K., Poznansky M.C. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17561-17566.
51. Huijbers E.J., Ringvall M., Femel J., Kalamajski S., Lukinius A., Abrink M., Hellman L., Olsson A.K. Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J. 2010, 24:4535-4544.
52. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
53. Ishizaki H., Tsunoda T., Wada S., Yamauchi M., Shibuya M., Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin. Cancer Res. 2006, 12:5841-5849.
54. Jarosz M., Jazowiecka-Rakus J., Cichon T., Glowala-Kosinska M., Smolarczyk R., Smagur A., Malina S., Sochanik A., Szala S. Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents. Gene Ther. 2013, 20:262-273.
55. Jellbauer S., Panthel K., Hetrodt J.H., Russmann H. CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma. PLoS ONE 2012, 7:e34214.
56. Jensen T.O., Schmidt H., Moller H.J., Hoyer M., Maniecki M.B., Sjoegren P., Christensen I.J., Steiniche T. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J. Clin. Oncol. 2009, 27:3330-3337.
57. Jiang C., Xiong W., Lu B.Y., Gonda M.A., Chang J.Y. Synthesis and immune response of non-native isomers of vascular endothelial growth factor. Biochemistry 2010, 49:6550-6556.
58. Kamstock D., Elmslie R., Thamm D., Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol. Immunother. 2007, 56:1299-1309.
59. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W., Schellhammer P.F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363:411-422.
60. Kaplan C.D., Kruger J.A., Zhou H., Luo Y., Xiang R., Reisfeld R.A. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine 2006, 24:6994-7002.
61. Ko J.S., Zea A.H., Rini B.I., Ireland J.L., Elson P., Cohen P., Golshayan A., Rayman P.A., Wood L., Garcia J., Dreicer R., Bukowski R., Finke J.H. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009, 15:2148-2157.
62. Kyutoku M., Nakagami H., Koriyama H., Tomioka H., Nakagami F., Shimamura M., Kurinami H., Zhengda P., Jo D.H., Kim J.H., Takakura N., Morishita R. Development of novel DNA vaccine for VEGF in murine cancer model. Sci. Rep. 2013, 3:3380.
63. Lee S.H., Mizutani N., Mizutani M., Luo Y., Zhou H., Kaplan C., Kim S.W., Xiang R., Reisfeld R.A. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol. Immunother. 2006, 55:1565-1574.
64. Lennerz V., Gross S., Gallerani E., Sessa C., Mach N., Boehm S., Hess D., von B.L., Knuth A., Ochsenbein A.F., Gnad-Vogt U., Zieschang J., Forssmann U., Woelfel T., Kaempgen E. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol. Immunother. 2014, 63:381-394.
65. Lewen S., Zhou H., Hu H.D., Cheng T., Markowitz D., Reisfeld R.A., Xiang R., Luo Y. A legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol. Immunother. 2008, 57:507-515.
66. Li B., Lalani A.S., Harding T.C., Luan B., Koprivnikar K., Huan T.G., Prell R., VanRoey M.J., Simmons A.D., Jooss K. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 2006, 12:6808-6816.
67. Li D.Y., Sorensen L.K., Brooke B.S., Urness L.D., Davis E.C., Taylor D.G., Boak B.B., Wendel D.P. Defective angiogenesis in mice lacking endoglin. Science 1999, 284:1534-1537.
68. Li Y., Wang M.N., Li H., King K.D., Bassi R., Sun H., Santiago A., Hooper A.T., Bohlen P., Hicklin D.J. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 2002, 195:1575-1584.
69. Liang P.H., Zhang K.Q., Xu G.L., Li Y.F., Wang L.F., Nie Z.L., Ye J., Wu G., Ge C.G., Jin F.S. Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth. Cancer Immunol. Immunother. 2010, 59:93-101.
70. Liu J.Y., Wei Y.Q., Yang L., Zhao X., Tian L., Hou J.M., Niu T., Liu F., Jiang Y., Hu B., Wu Y., Su J.M., Lou Y.Y., He Q.M., Wen Y.J., Yang J.L., Kan B., Mao Y.Q., Luo F., Peng F. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003, 102:1815-1823.
71. Lladser A., Ljungberg K., Tufvesson H., Tazzari M., Roos A.K., Quest A.F., Kiessling R. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Cancer Immunol. Immunother. 2010, 59:81-92.
72. Lladser A., Parraga M., Quevedo L., Carmen M.M., Silva S., Ferreira A., Billetta R., AF G.Q. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. Immunobiology 2006, 211:11-27.
73. Lu X.L., Jiang X.B., Liu R.E., Zhang S.M. The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10. Vaccine 2008, 26:5352-5357.
74. Luo Y., Markowitz D., Xiang R., Zhou H., Reisfeld R.A. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice. Vaccine 2007, 25:1409-1415.
75. Luo Y., Wen Y.J., Ding Z.Y., Fu C.H., Wu Y., Liu J.Y., Li Q., He Q.M., Zhao X., Jiang Y., Li J., Deng H.X., Kang B., Mao Y.Q., Wei Y.Q. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin. Cancer Res. 2006, 12:1813-1819.
76. Luo Y., Zhou H., Krueger J., Kaplan C., Lee S.H., Dolman C., Markowitz D., Wu W., Liu C., Reisfeld R.A., Xiang R. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 2006, 116:2132-2141.
77. Matejuk A., Leng Q., Chou S.T., Mixson A.J. Vaccines targeting the neovasculature of tumors. Vasc. Cell 2011, 3:7.
78. Melder R.J., Koenig G.C., Witwer B.P., Safabakhsh N., Munn L.L., Jain R.K. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 1996, 2:992-997.
79. Miyazawa M., Ohsawa R., Tsunoda T., Hirono S., Kawai M., Tani M., Nakamura Y., Yamaue H. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010, 101:433-439.
80. Morera Y., Bequet-Romero M., Ayala M., Lamdan H., Agger E.M., Andersen P., Gavilondo J.V. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 2008, 11:381-393.
81. Morera Y., Bequet-Romero M., Ayala M., Perez P.P., Castro J., Sanchez J., Alba J.S., Ancizar J., Cosme K., Gavilondo J.V. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine 2012, 30:368-377.
82. Morera Y., Bequet-Romero M., Ayala M., Velazco J.C., Perez P.P., Alba J.S., Ancizar J., Rodriguez M., Cosme K., Gavilondo J.V. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine 2010, 28:3453-3461.
83. Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 2011, 11:702-711.
84. Motz G.T., Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013, 39:61-73.
85. Nair S., Boczkowski D., Moeller B., Dewhirst M., Vieweg J., Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003, 102:964-971.
86. Niethammer A.G., Lubenau H., Mikus G., Knebel P., Hohmann N., Leowardi C., Beckhove P., Akhisaroglu M., Ge Y., Springer M., Grenacher L., Buchler M.W., Koch M., Weitz J., Haefeli W.E., Schmitz-Winnenthal F.H. Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-receptor 2 in patients with stage IV and locally advanced pancreatic cancer. BMC Cancer 2012, 12:361.
87. Niethammer A.G., Xiang R., Becker J.C., Wodrich H., Pertl U., Karsten G., Eliceiri B.P., Reisfeld R.A. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 2002, 8:1369-1375.
88. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
89. Ohm J.E., Gabrilovich D.I., Sempowski G.D., Kisseleva E., Parman K.S., Nadaf S., Carbone D.P. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003, 101:4878-4886.
90. Okaji Y., Tsuno N.H., Kitayama J., Saito S., Takahashi T., Kawai K., Yazawa K., Asakage M., Hori N., Watanabe T., Shibata Y., Takahashi K., Nagawa H. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci. 2004, 95:85-90.
91. Okaji Y., Tsuno N.H., Saito S., Yoneyama S., Tanaka M., Nagawa H., Takahashi K. Vaccines targeting tumour angiogenesis-a novel strategy for cancer immunotherapy. Eur. J. Surg. Oncol. 2006, 32:363-370.
92. Okaji Y., Tsuno N.H., Tanaka M., Yoneyama S., Matsuhashi M., Kitayama J., Saito S., Nagura Y., Tsuchiya T., Yamada J., Tanaka J., Yoshikawa N., Nishikawa T., Shuno Y., Todo T., Saito N., Takahashi K., Nagawa H. Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy. Eur. J. Cancer 2008, 44:383-390.
93. Okamoto I., Arao T., Miyazaki M., Satoh T., Okamoto K., Tsunoda T., Nishio K., Nakagawa K. Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci. 2012, 103:2135-2138.
94. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
95. Osada T., Chong G., Tansik R., Hong T., Spector N., Kumar R., Hurwitz H.I., Dev I., Nixon A.B., Lyerly H.K., Clay T., Morse M.A. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 2008, 57:1115-1124.
96. Pages F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautes-Fridman C., Fridman W.H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29:1093-1102.
97. Pardali E., van der Schaft D.W., Wiercinska E., Gorter A., Hogendoorn P.C., Griffioen A.W., ten D.P. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 2011, 30:334-345.
98. Piao Y., Liang J., Holmes L., Henry V., Sulman E., de Groot J.F. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin. Cancer Res. 2013, 19:4392-4403.
99. Plum S.M., Holaday J.W., Ruiz A., Madsen J.W., Fogler W.E., Fortier A.H. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 2000, 19:1294-1303.
100. Plum S.M., Vu H.A., Mercer B., Fogler W.E., Fortier A.H. Generation of a specific immunological response to FGF-2 does not affect wound healing or reproduction. Immunopharmacol. Immunotoxicol. 2004, 26:29-41.
101. Rad F.H., Le B.H., Paturance S., Larcier P., Genne P., Ryffel B., Bensussan A., Bizzini B., Gallo R.C., Zagury D., Uzan G. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2837-2842.
102. Ramage J.M., Metheringham R., Conn A., Spendlove I., Moss R.S., Patton D.T., Murray J.C., Rees R.C., Durrant L.G. Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. Int. J. Cancer 2004, 110:245-250.
103. Ren S., Fengyu S.Zuo, Zhao M., Wang X., Wang X., Chen Y., Wu Z., Ren Z. Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine. Vaccine 2011, 29:5802-5811.
104. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431.
105. Ruan Z., Yang Z., Wang Y., Wang H., Chen Y., Shang X., Yang C., Guo S., Han J., Liang H., Wu Y. DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. J. Immunother. 2009, 32:486-491.
106. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355:2542-2550.
107. Scaldaferri F., Vetrano S., Sans M., Arena V., Straface G., Stigliano E., Repici A., Sturm A., Malesci A., Panes J., Yla-Herttuala S., Fiocchi C., Danese S. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009, 136:585-595.
108. Schoenfeld J., Jinushi M., Nakazaki Y., Wiener D., Park J., Soiffer R., Neuberg D., Mihm M., Hodi F.S., Dranoff G. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010, 70:10150-10160.
109. Schoenfeld J.D., Dranoff G. Anti-angiogenesis immunotherapy. Hum. Vaccin. 2011, 7:976-981.
110. Seaman S., Stevens J., Yang M.Y., Logsdon D., Graff-Cherry C., St B. Croix, genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007, 11:539-554.
111. Seavey M.M., Maciag P.C., Al-Rawi N., Sewell D., Paterson Y. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+breast tumors in a mouse model. J. Immunol. 2009, 182:5537-5546.
112. Shrimali R.K., Yu Z., Theoret M.R., Chinnasamy D., Restifo N.P., Rosenberg S.A. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010, 70:6171-6180.
113. Stetler-Stevenson W.G., Seo D.W. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol. Med. 2005, 11:97-103.
114. Struman I., Bentzien F., Lee H., Mainfroid V., D'Angelo G., Goffin V., Weiner R.I., Martial J.A. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1246-1251.
115. Su J.M., Wei Y.Q., Tian L., Zhao X., Yang L., He Q.M., Wang Y., Lu Y., Wu Y., Liu F., Liu J.Y., Yang J.L., Lou Y.Y., Hu B., Niu T., Wen Y.J., Xiao F., Deng H.X., Li J., Kan B. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res. 2003, 63:600-607.
116. Takahashi A., Kono K., Ichihara F., Sugai H., Fujii H., Matsumoto Y. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol. Immunother. 2004, 53:543-550.
117. Tan G.H., Tian L., Wei Y.Q., Zhao X., Li J., Wu Y., Wen Y.J., Yi T., Ding Z.Y., Kan B., Mao Y.Q., Deng H.X., Li H.L., Zou C.H., Fu C.H. Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. Int. J. Cancer 2004, 112:701-706.
118. Tan G.H., Wei Y.Q., Tian L., Zhao X., Yang L., Li J., He Q.M., Wu Y., Wen Y.J., Yi T., Ding Z.Y., Kan B., Mao Y.Q., Deng H.X., Li H.L., Zhou C.H., Fu C.H., Xiao F., Zhang X.W. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur. J. Immunol. 2004, 34:2012-2021.
119. Thairu N., Kiriakidis S., Dawson P., Paleolog E. Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. Angiogenesis 2011, 14:223-234.
120. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., Berger A., Bruneval P., Fridman W.H., Pages F., Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011, 71:1263-1271.
121. van Beijnum J.R., Dings R.P., van der Linden E., Zwaans B.M., Ramaekers F.C., Mayo K.H., Griffioen A.W. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006, 108:2339-2348.
122. van den Eertwegh A.J., Versluis J., van den Berg H.P., Santegoets S.J., van Moorselaar R.J., van der Sluis T.M., Gall H.E., Harding T.C., Jooss K., Lowy I., Pinedo H.M., Scheper R.J., Stam A.G., von Blomberg B.M., de Gruijl T.D., Hege K., Sacks N., Gerritsen W.R. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012, 13:509-517.
123. van der Schaft D.W., Toebes E.A., Haseman J.R., Mayo K.H., Griffioen A.W. Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood 2000, 96:176-181.
124. Vandercappellen J., Van D.J., Struyf S. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev. 2011, 22:1-18.
125. Vansteenkiste J.F., Cho B., Vanakesa T., De Pas T., Zielinski M., Kim M., Jassem J., Yoshimura M., Dahabreh J., Nakayama H., Havel L., Kondo H., Mitsudomi T., Zarogoulidis K., Gladkov O.A., Spiessens B., Brichard V., Debruyne C., Therasse P., Altorki N.K. MAGRIT, a double-blind, randomized, placebo-controlled phase III study to test the efficacy of the RecMAGE-A3+AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC). Ann. Oncol. 2014, 25(suppl 4):1iv409-iv416.
126. Vicari D., Foy K.C., Liotta E.M., Kaumaya P.T. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J. Biol. Chem. 2011, 286:13612-13625.
127. von M.Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., Wiedenmann B., Hocker M., Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 2003, 95:437-448.
128. Wada S., Tsunoda T., Baba T., Primus F.J., Kuwano H., Shibuya M., Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005, 65:4939-4946.
129. Wang B., Kaumaya P.T., Cohn D.E. Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol. Oncol. 2010, 119:564-570.
130. Wang Y.S., Wang G.Q., Wen Y.J., Wang L., Chen X.C., Chen P., Kan B., Li J., Huang C., Lu Y., Zhou Q., Xu N., Li D., Fan L.Y., Yi T., Wu H.B., Wei Y.Q. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1. Clin. Cancer Res. 2007, 13:6779-6787.
131. Wei Y.Q., Huang M.J., Yang L., Zhao X., Tian L., Lu Y., Shu J.M., Lu C.J., Niu T., Kang B., Mao Y.Q., Liu F., Wen Y.J., Lei S., Luo F., Zhou L.Q., Peng F., Jiang Y., Liu J.Y., Zhou H., Wang Q.R., He Q.M., Xiao F., Lou Y.Y., Xie X.J., Li Q., Wu Y., Ding Z.Y., Hu B., Hu M., Zhang W. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11545-11550.
132. Wei Y.Q., Wang Q.R., Zhao X., Yang L., Tian L., Lu Y., Kang B., Lu C.J., Huang M.J., Lou Y.Y., Xiao F., He Q.M., Shu J.M., Xie X.J., Mao Y.Q., Lei S., Luo F., Zhou L.Q., Liu C.E., Zhou H., Jiang Y., Peng F., Yuan L.P., Li Q., Wu Y., Liu J.Y. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat. Med. 2000, 6:1160-1166.
133. Wood L.M., Pan Z.K., Guirnalda P., Tsai P., Seavey M., Paterson Y. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Cancer Immunol. Immunother. 2011, 60:931-942.
134. Xiang R., Mizutani N., Luo Y., Chiodoni C., Zhou H., Mizutani M., Ba Y., Becker J.C., Reisfeld R.A. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005, 65:553-561.
135. Yang X., Zhu H., Hu Z. Dendritic cells transduced with TEM8 recombinant adenovirus prevents hepatocellular carcinoma angiogenesis and inhibits cells growth. Vaccine 2010, 28:7130-7135.
136. Yoshimura K., Minami T., Nozawa M., Uemura H. Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Br. J. Cancer 2013, 108:1260-1266.
137. Yuan J., Zhou J., Dong Z., Tandon S., Kuk D., Panageas K.S., Wong P., Wu X., Naidoo J., Page D.B., Wolchok J.D., Hodi F.S. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol. Res. 2014, 2:127-132.
138. Zhang X.P., Yang L., Shi H.S., Zhao X., Deng H.X., Xiao W.J., Mao Y.Q., Kan B., Liu Y.L., Zhang S., Li Z.M., Zhang J., Wei Y.Q. An N-, C-terminally truncated basic fibroblast growth factor and LPD (liposome-polycation-DNA) complexes elicits a protective immune response against murine colon carcinoma. Cancer Biol. Ther. 2010, 10:276-281.
139. Zhou H., Luo Y., Mizutani M., Mizutani N., Reisfeld R.A., Xiang R. T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood 2005, 106:2026-2032.
140. Zhu K., Qin H., Cha S.C., Neelapu S.S., Overwijk W., Lizee G.A., Abbruzzese J.L., Hwu P., Radvanyi L., Kwak L.W., Chang D.Z. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 2007, 25:7955-7961.
141. Zhuang X., Ahmed F., Zhang Y., Ferguson H.J., Steele J.C., Steven N.M., Nagy Z., Heath V.L., Toellner K.M., Bicknell R. Robo4 vaccines induce antibodies that retard tumor growth. Angiogenesis 2014, 1:83-95.